Brief: Knight Therapeutics Reports Q4 Loss Per Share Of $0.049
30/03/2020 22:11
March 30 (Reuters) - Knight Therapeutics Inc GUD.TO :
* KNIGHT THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR END
2019
RESULTS
* KNIGHT THERAPEUTICS - QTRLY LOSS PER SHARE $0.049
Source text for Eikon: ID:nGNX1S2P3v
Further company coverage: GUD.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Knight Therapeutics
See all newsBrief: Knight Therapeutics Announces Regulatory Approval Of Niktimvo In Brazil
Brief: Knight Therapeutics - Launches Tavalisse In Brazil For Chronic Immune Thrombocytopenia
Brief: Knight Therapeutics Enters Into Exclusive Distribution Agreement With Kyowa Kirin International For Poteligeo® (Mogamulizumab)
Brief: Knight Therapeutics Announces Regulatory Approval Of Tavalisse® In Colombia
Brief: Knight Therapeutics Announces Supplemental Regulatory Submission For Minjuvi In Brazil